Health

The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month

STUDIO CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month…

1 month ago

Curaechoice and Fast Pace Health Partner to Expand Affordable Healthcare Access Across Multiple States

Curaechoice members now have enhanced access to covered services at over 300 Fast Pace Health clinics at $0 cost February…

1 month ago

The Integrated Healthcare Association Recognizes California Provider Organizations for Medicare Advantage Performance

OAKLAND, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Integrated Healthcare Association (IHA) today announced top-performing provider organizations and those…

1 month ago

IBA TRANSPARENCY NOTIFICATION

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February…

1 month ago

Amwell to Participate in Upcoming Investor Conference

February 24, 2026 17:00 ET  | Source: Amwell BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading…

1 month ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

February 24, 2026 16:30 ET  | Source: Cardiff Oncology, Inc. Reported positive update from Phase 2 CRDF-004 trial in first-line…

1 month ago

Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term…

1 month ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

February 23, 2026 18:15 ET  | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,…

1 month ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative…

1 month ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

February 23, 2026 17:10 ET  | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…

1 month ago